文献速递肾小球疾病肾移植

促红细胞生成素通过抑制T滤泡辅助细胞分化减少自身抗体和同种抗体

Erythropoietin Reduces Auto- and Alloantibodies by Inhibiting T Follicular Helper Cell Differentiation.
PubMed 文献 · J Am Soc Nephrol · 2021-07-14

本研究利用体外培养、小鼠器官移植和狼疮肾炎模型,发现促红细胞生成素(EPO)通过T细胞EPO受体(EPOR)和STAT5依赖性机制抑制T滤泡辅助细胞(TFH)分化,减少生发中心B细胞和致病性抗体产生,并在狼疮模型中减轻自身免疫性肾小球肾炎,提示EPO可能用于治疗抗体介导的肾脏疾病。

要点

  • EPO通过T细胞EPOR抑制TFH分化和生发中心B细胞形成。
  • EPO减少T细胞依赖性自身抗体和同种抗体,但不影响T非依赖性抗体。
  • EPO在狼疮模型中减轻自身免疫性肾小球肾炎。

核心结论

  • EPO通过抑制TFH依赖性抗体形成,减少自身抗体和同种抗体,可能用于治疗抗体介导的肾脏疾病。

研究设计与样本

  • 研究采用体外培养系统、小鼠器官移植模型、狼疮肾炎模型及T细胞或B细胞条件性EPOR缺陷小鼠。

主要发现

  • 在野生型小鼠中,重组EPO抑制针对模型抗原和强多克隆刺激的初次T细胞依赖性体液免疫,但不改变T非依赖性体液免疫应答。
  • EPO在强同种异体器官移植模型系统中显著损害二次体液免疫。
  • EPO的作用需要T细胞而非B细胞表达EPOR,并导致生发中心B细胞和TFH频率降低。
  • EPO通过STAT5依赖性机制直接阻止TFH分化和功能,减少CD4+ T细胞Bcl6表达。
  • 在狼疮模型中,EPO减少TFH、生发中心B细胞和自身抗体产生,并减轻自身免疫性肾小球肾炎;体外研究证实EPO阻止人TFH细胞分化。

临床怎么用

  • EPO可能作为减少致病性抗体产生的潜在治疗策略,用于抗体介导的肾脏疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although high-affinity IgG auto- and alloantibodies are important drivers of kidney inflammation that can result in ESKD, therapeutic approaches that effectively reduce such pathogenic antibodies remain elusive. Erythropoietin (EPO) has immunomodulatory functions, but its effects on antibody production are unknown. METHODS: We assessed the effect and underlying mechanisms of EPO/EPO receptor (EPOR) signaling on primary and secondary, T cell-dependent and T-independent antibody formation using in vitro culture systems, murine models of organ transplantation and lupus nephritis, and mice conditionally deficient for the EPOR expressed on T cells or B cells. RESULTS: In wild-type mice, recombinant EPO inhibited primary, T cell-dependent humoral immunity to model antigens and strong, polyclonal stimuli, but did not alter T-independent humoral immune responses. EPO also significantly impaired secondary humoral immunity in a potent allogeneic organ transplant model system. The effects required T cell, but not B cell, expression of the EPOR and resulted in diminished frequencies of germinal center (GC) B cells and T follicular helper cells (TFH). In vitro and in vivo experiments showed that EPO directly prevented TFH differentiation and function via a STAT5-dependent mechanism that reduces CD4+ T cell expression of Bcl6. In lupus models, EPO reduced TFH, GC B cells, and autoantibody production, and abrogated autoimmune glomerulonephritis, demonstrating clinical relevance. In vitro studies verified that EPO prevents differentiation of human TFH cells. CONCLUSIONS: Our findings newly demonstrate that EPO inhibits TFH-dependent antibody formation, an observation with potential implications for treating antibody-mediated diseases, including those of the kidney.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Guglielmo C, Bin S, Cantarelli C, et al. Erythropoietin Reduces Auto- and Alloantibodies by Inhibiting T Follicular Helper Cell Differentiation. J Am Soc Nephrol. 2021. PMID: 34261755. doi:10.1681/ASN.2021010098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。